FLT3 inhibitors in acute myeloid leukemia: A network meta-analysis of phase III trials.

医学 米多司他林 肿瘤科 髓系白血病 内科学 化疗 生存分析 危险系数 人口 随机对照试验 安慰剂 比例危险模型 阿糖胞苷 髓样 临床研究阶段 化疗方案 总体生存率 外科 临床试验 维持疗法
作者
Sameer Bhimani,Taimoor Nasir,Aniqa Baloch,Swapnil Sunil Surpur,Satish Ahuja,Waleed Iftikhar,Muhammad Umair Anjum,Douglas Klamp
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl)
标识
DOI:10.1200/jco.2026.44.16_suppl.e18505
摘要

e18505 Background: FLT3 inhibitors improve outcomes in FLT3-mutated acute myeloid leukemia (AML); however, no head-to-head phase III comparisons exist among available agents. Updated randomized data from RATIFY (midostaurin), QUANTUM-First (quizartinib), and ADMIRAL (gilteritinib) enable indirect comparative effectiveness assessment of FLT3-directed therapy across treatment settings. Methods: A frequentist network meta-analysis was performed using phase III randomized trials enrolling FLT3-mutated AML patients. Reported hazard ratios (HRs) for overall survival (OS) and event-free survival (EFS) were extracted. Random-effects network models estimated treatment effects versus chemotherapy and ranking probabilities (P-scores). The evidence network was anchored through shared chemotherapy control arms. Frontline survival comparisons included RATIFY and QUANTUM-First; ADMIRAL was analyzed separately due to relapse/refractory (R/R) population differences. Results: Across five comparisons (~1,600 patients), midostaurin (HR 0.78; 95% CI 0.63–0.96) and quizartinib (HR 0.78; 95% CI 0.62–0.98) each significantly reduced mortality versus placebo in frontline AML. Indirect comparison demonstrated no detectable difference between the two agents (HR 1.00; 95% CI 0.73–1.36). Ranking analysis assigned near-identical P-scores to midostaurin and quizartinib (0.74 vs 0.74), supporting equivalent likelihood of benefit in the frontline setting. In the R/R population, gilteritinib significantly improved survival compared with salvage chemotherapy (HR 0.64; 95% CI 0.49–0.83). Conclusions: Midostaurin and quizartinib demonstrate equivalent survival probability in frontline FLT3-mutated AML based on current randomized evidence, challenging assumptions of superiority among FLT3 inhibitors. Gilteritinib remains an effective salvage option in relapsed disease but reflects a distinct treatment setting rather than comparative frontline potency. Interpretation is limited by cross-trial differences in age eligibility, FLT3 subtype inclusion, chemotherapy backbones, and trial era, which may affect transitivity assumptions in this network meta-analysis. This frequentist network meta-analysis incorporates mature survival updates from RATIFY and QUANTUM-First and demonstrates near-identical ranking probabilities (P-scores 0.74 vs 0.74), supporting equivalent frontline survival benefit of midostaurin and quizartinib. Future head-to-head trials incorporating MRD response and transplant-adjusted outcomes are warranted to refine sequencing strategies for FLT3-directed therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
情怀的应助被白白白采纳,获得10
1秒前
小何发布了新的文献求助10
1秒前
1秒前
1秒前
大模型的应助被郝丽伟采纳,获得10
1秒前
小蛋完成签到,获得积分10
2秒前
超级无敌的应助被Happyocean采纳,获得10
2秒前
2秒前
3秒前
耶耶完成签到,获得积分10
3秒前
3秒前
CodeCraft的应助被WWT采纳,获得10
3秒前
3秒前
3秒前
冬瓜鑫发布了新的文献求助10
3秒前
秋风的应助被qqqxxx采纳,获得20
4秒前
4秒前
zzhou发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
moaner完成签到,获得积分10
5秒前
5秒前
斯文败类的应助被Wink213采纳,获得10
5秒前
石愚志发布了新的文献求助10
5秒前
高大鸣凤完成签到,获得积分10
6秒前
木子完成签到,获得积分10
6秒前
小马甲的应助被飘逸迎丝采纳,获得10
6秒前
飞蚁完成签到 ,获得积分10
6秒前
7秒前
李旭珍最爱的香香宝贝完成签到,获得积分10
7秒前
顺颂时祺发布了新的文献求助10
7秒前
mujinhuanxin完成签到,获得积分10
7秒前
张yusong完成签到,获得积分20
7秒前
7秒前
8秒前
一颗石榴发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124